drugset / Trial / NCT02187809

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

NCT02187809

Phase 3 Terminated 3 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

To investigate the long-term safety and tolerability of clobazam when administered for 1 year as adjunctive therapy in paediatric patients aged ≥1 to ≤16 years with Dravet Syndrome.

Timeline

Start
2015-03
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Clobazam Small molecule 2 mg/kg Oral
Subject Clobazam Small molecule 80 mg Oral

Indications